An open science pathway for drug marketing authorization—Registered drug approval

Florian Naudet and co-authors propose a pathway involving registered criteria for evaluation and approval of new drugs.

Publisher’s note: This Perspective is one of the two winning Essays of the “Reimagine biomedical research for a healthier future” Essay challenge, launched by the Health Research Alliance in partnership with PLOS. This publication is coordinated with that of the other winning Essay in PLOS Biology. The competition was intended to spark a discussion around the future of biomedical research; publication does not imply endorsement from HRA or PLOS.